United States - English - NLM (National Library of Medicine)

accord healthcare inc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin 40 mg in 80 ml - mitomycin for injection is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes. insufficient data from clinical studies of mitomycin are available for patients 65 years of age and older to determine whether they respond differently than younger patients. postmarketing surveillance suggests that elderly patients may be more susceptible than younger patients to injection site reactions (see adverse reactions: integument and mucous mem

United States - English - NLM (National Library of Medicine)

mylan institutional llc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin 40 mg in 80 ml - mitomycin for injection, usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Israel - English - Ministry of Health

dexcel ltd, israel - mitomycin c (crystalline) - powder for solution for injection - mitomycin c (crystalline) 10 mg/vial - mitomycin - mitomycin - remission of subjective and objective symptoms assocciated with the following diseases: - chronic lymphocytic leukemia, - chronic myelocytic leukemia, - gastric cancer, - colorectal cancer, - lung cancer, - pancreatic cancer, - liver cancer, - cervix cancer, - cancer of the endometrium, - breast cancer, - head and neck tumor, - bladder tumor.

Israel - English - Ministry of Health

dexcel ltd, israel - mitomycin c ( crystalline ) - powder for solution for injection - mitomycin c ( crystalline ) 2 mg/vial - mitomycin - mitomycin - remission of subjective and objective symptoms assocciated with the following diseases: chronic lymphocytic leukemia, chronic myelocytic leukemia, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervix cancer, cancer of the endometrium, breast cancer, head and neck tumor and bladder tumor.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 20mg;   - powder for injection - 20 mg - active: mitomycin 20mg   excipient: mannitol - mitomycin for injection usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin for injection usp is not recommended to replace appropriate surgery and/or radiotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 5mg;   - powder for injection - 5 mg - active: mitomycin 5mg   excipient: mannitol - mitomycin for injection usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin for injection usp is not recommended to replace appropriate surgery and/or radiotherapy.

Malta - English - Medicines Authority

accord healthcare limited - mitomycin - powder for solution for infusion or injection - mitomycin 2 mg - antineoplastic agents